The severity of the PORD clinical phenotypes depends upon the mutated amino acid residue and its location within the three cofactor binding domains, i.e., the FAD, FMN and NADPH binding domains of the POR enzyme. The gene discussed is FMN1; the disease is congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency.